Course

The Importance of Assessing Disease Activity in PsA: A Look at Our Options

In this issue of Rheumatology Nurse Practice, we explore the options available to measure and track disease activity levels in patients with psoriatic arthritis and offer guidance on how these can be smoothly incorporated into routine clinical practice.

0 Lessons

The Importance of Assessing Disease Activity in PsA: A Look at Our Options

TARGET AUDIENCE

This activity has been designed to meet the educational needs of nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.

ACTIVITY DESCRIPTION

In this issue of Rheumatology Nurse Practice, we explore the options available to measure and track disease activity levels in patients with psoriatic arthritis and offer guidance on how these can be smoothly incorporated into routine clinical practice.

LEARNING OBJECTIVES

After participating in the activity, learners should be better able to:

  • Analyze the reasons why minimal disease activity may be a more appropriate disease activity target than remission in patients with psoriatic arthritis (PsA)
  • Identify common features of disease activity measures used to assess the progress of patients with PsA
  • Assess the viability of incorporating one or more validated PsA disease activity measures into your clinical practice
  • Discuss the potential benefits of non-drug related treatment options such as climatotherapy for patients with PsA

DISCLOSURE STATEMENT

According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

RELATIONSHIPS ARE ABBREVIATED AS FOLLOWS:

E: Educational planning committee
G: Grant/research support recipient
A: Advisor/review panel member
C: Consultant
S: Stock shareholder
SB: Speaker bureau
PE: Promotional event talks
H: Honoraria
O: Other

DISCLOSURES AS FOLLOWS:

Linda Grinnell-Merrick, MS, NP-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Celgene, Janssen, Novartis, Sanofi/SB; Abbvie, Celgene, Lily, Pfizer, Sanofi/C.

Monica Richey, MSN, ANP-CP/GNP, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Mallinckrodt/SB; Celgene, Novartis/C.

Eileen Lydon, ANP-BC, MA, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Novartis, AbbVie/SB; Celgene, Horizon, AbbVie/C.

Amanda Mixon, PA-C, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Abbvie, Celgene, Lilly, Novartis/C, SB; Janssen/SB; Pfizer, Sanofi/C.

PLANNING COMMITTEE

Kim Cheramie, MSN, RN-BC, Lead Nurse Planner, Rheumatology Nurses Society, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.
Alexandra Howson, MA, PhD, CHCP, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

INDEPENDENT CLINICAL PEER REVIEWER

This newsletter was reviewed by Michelle Bastien, MSN, NP-C. Ms. Bastien has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

OFF-LABEL PRODUCT DISCLOSURE

This activity will review off-label or investigational information of the following: Apremilast

ACCREDITATION AND CREDIT DESIGNATION

Nurses

Rheumatology Nurses Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).

Rheumatology Nurses Society designates this educational activity for:
3.1 contact hours
2.5 pharmacotherapeutic contact hours

METHOD OF PARTICIPATION

There are no fees to participate in the activity. Participants must review the activity information, including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please go to rnsnurse.com/rnpce and complete the post-test (achieving a passing grade of 70% or greater) and program evaluation. Your certificate will be generated immediately.

COPYRIGHT

© 2019. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).